Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33521378&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Obes+Med 2021 ; 22 (ä): 100317 Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Hypoxia-inducible factor (HIF): The link between obesity and COVID-19 #MMPMID33521378
AbdelMassih A; Yacoub E; Husseiny RJ; Kamel A; Hozaien R; El Shershaby M; Rajab M; Yacoub S; Eid MA; Elahmady M; Gadalla M; Mokhtar S; Hassan AA; Abou-Zeid AS; Hussein M; Aboushadi N; Emad N; Zahra N; Hassan A; Hussein E; Ibrahim N; El Nahhas N; Elahmady T; Khallaf M; Mustafa H; Anis N; Albehairy M; Hanna F; Moris L; Ye J
Obes Med 2021[Mar]; 22 (ä): 100317 PMID33521378show ga
The COVID-19 death toll has involved to date more than 1 million confirmed deaths. The death rate is even higher in the obese COVID-19 patients, as a result of hypoxia, due to the interplay between adipose tissue hypoxia and obstructive sleep apnea. The discrepancy of manifestations seen in COVID-19 seems to be mediated by a differential immune response rather than a differential viral load. One of the key players of the immune response is HIF. HIF-1beta is a stable constitutively expressed protein in the nucleus; and under hypoxic changes, its activity is unaffected, whereas the HIF-alpha subunit has a short half-life and because of its degradation by an enzyme known as propyl hydroxylase; under hypoxic conditions, propyl hydroxylase gets deactivated thus leading to the stabilization of HIF-1alpha. As mentioned before, HIF-1alpha expression is triggered by hypoxic states, this crippling condition will aggravate the pro-inflammatory characteristics of HIF-1alpha. The vast majority of decompensated COVID19 cases manifest with drastic lung injury and severe viral pneumonia, the infection-induced hypoxia will the existing hypoxia in obesity. This will additionally augment HIF-1alpha levels that will provoke the already existing cytokines' storm to fulminant. Consequently, this will directly correlate the effect of a hypoxic environment with the increase of HIF-1alpha level. HIFa exists in two main isoforms HIF-1alpha and HIF-2alpha. HIF-1alpha and HIF-2alpha act in distinct ways in how they work on different target genes. For example, HIF-2alpha may act on hemopoietin genes (heme-regulating genes); while HIF-1alpha acts on EPO. HIF-1alpha release seems to be markedly augmented in obesity due to adipose tissue hypoxia and obstructive sleep apnea resulting in cyclic hypoxia. HIF-1alpha can also be secreted by direct viral proteolytic effects. Whereas, HIF-2alpha is stimulated by chronic hypoxia. HIF-1alpha exerts detrimental effects on the immune system, characterized by unopposed pro-inflammation at the macrophages, dendritic cells, T cells, and complement levels resulting in cytokines' storm, which is linked to the poor outcomes of COVID-19. On the other hand, HIF-2alpha role is regulatory and largely opposes the actions mediated by HIF-1alpha. In view of this, inhibiting HIF-1alpha release or switching its production to HIF-2alpha by natural products such as resveratrol or by synthetic drugs, offer a good therapeutic strategy that can prevent COVID-19 worst outcome in infected patients. The approach of breaking the vicious circle between lung damage-induced hypoxia and HIF-1alpha pro-inflammatory stimulant through drugs is considered to be extremely promising as a therapeutic manner to combat further deterioration of COVID19 cases.